Pharmacy in Boulder, CO
Quark Pharmaceuticals. Is a clinical-stage pharmaceutical firm that is a leader in the discovery and development of novel RNAi-based therapeutics. QPI-1002 is the 1st synthetic siRNA to be evaluated following systemic administration in human clinical trials, and is tailored to temporarily inhibit expression of the stress-response gene, p53. QPI-1002 is being studied under two INDs for two indications - the prevention of acute kidney injury (AKI) in patients undergoing major cardiovascular surgery, and the prophylaxis of delayed graft function (DGF) in renal transplant patients.
read moreWe have a fully integrated Research and Development team with a proven track record of translating our innovations in siRNA therapeutics from discovery to the clinic. We have full capabilities in the areas of cell and molecular biology, protein biochemistry, monoclonal antibody technology, bioinformatics, animal pharmacology, histopathology including immunohistochemistry and in situ hybridization, and drug delivery. Our development teams, to-date have progressed drug candidates through INDs into advanced clinical studies in different disease indications.
read moreQuark Pharmaceuticals, Inc. is a late-stage pharmaceutical company and a leader in the discovery and development of novel small interfering RNA (siRNA) therapeutics. We aim to improve the lives of millions of patients by harnessing the natural mechanism of siRNAs. By inhibiting key disease-related genes, we can address serious unmet medical needs that could not be dreamed curable before the advent of siRNA therapies. Quark's late-stage pipeline includes siRNA therapies for renal protection in cardio-renal disease and neuroprotection in ophthalmology, with two products currently in Phase 3 clinical trials.